GCM
ADPT icon

Graham Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Graham Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,202
Closed -$142K – 1230
2026
Q1 		$142K Sell
10,202
-36,323
-78% -$579K ﹤0.01% 1001
2025
Q4 		$756K Buy
+46,525
New +$759K 0.02% 470
2025
Q2 		– Sell
-17,669
Closed -$131K – 1272
2025
Q1 		$131K Sell
17,669
-23,245
-57% -$179K ﹤0.01% 1184
2024
Q4 		$245K Buy
+40,914
New +$226K ﹤0.01% 1013
2022
Q4 		– Sell
-142,417
Closed -$1.01M – 1020
2022
Q3 		$1.01M Buy
+142,417
New +$1.34M 0.04% 483
2021
Q4 		– Sell
-12,693
Closed -$431K – 528
2021
Q3 		$431K Buy
+12,693
New +$459K 0.02% 104

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Graham Capital Management's ADPT Position: Q2 2026 in Review

Graham Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 10,202 shares — an estimated $142K sold.

Graham Capital Management first reported a position in ADPT in Q3 2021 and held it in 6 quarters. The position peaked at $1.01M in Q3 2022. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Graham Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 10,202 Adaptive Biotechnologies shares in Q2 2026, an estimated $142K.
  • Graham Capital Management first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 6 quarters.
  • Graham Capital Management's Adaptive Biotechnologies position peaked at $1.01M in Q3 2022.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.